Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, Masatoshi Kudo, Han Chu Lee, Adam C. Yopp, Jian Zhou, Lu Wang, Xiaoyu Wen, Jeong Heo, Won Young Tak, Shinichiro Nakamura, Kazushi Numata, Thomas Uguen, David Hsiehchen, Edward Cha, Stephen P. Hack, Qinshu Lian, Ning Ma, Jessica Spahn, Yulei Wang, Lyndia C. Wu, Pierce K. H. Chow, Alexander Thompson, Mark Danta, Pirooz Poursoltan, Andrew Ddembe Kiberu, Renuka Chittajallu, Siddarth Sood, Rudolf Stauber, Matthias Pinter, Markus Peck‐Radosavljevic, Jochen Decaestecker, Pieter‐Jan Cuyle, Gontran Verset, Hans Van Vlierberghe, Sérgio de Azevedo, Livia Andrade, Ademar Cunha Júnior, Luiza Dib Batista Bugiato Faria, Cheng Tzu Yen, Leandro M. Colli, Jamil Asselah, Petr Kavan, Vladimir Marquez, Mayur Brahmania, Qiang Li, Bao-Cai Xing, Yabing Guo, Zhendong Chen, Haitao Zhao, Tao Peng, Liming Wang, Lu Wang, Hongming Liu, Feixiang Wu, Lun–Xiu Qin, Qichang Zheng, Jieer Ying, Haitao Li, Tianfu Wen, Shukui Qin, Xiaoyu Wen, Yunpeng Liu, Minshan Chen, Boqing Wang, Yuxian Bai, Yifu He, Hong Zhao, Dong Zhou, Chaoliu Dai, Gao‐Jun Teng, Shuzhong Cui, Yi Gao, Xizhi Zhang, Zheng Lu, Tao Yin, Youming Ding, Weidong Jia, Yongxiang Xia, Beicheng Sun, Qiang Xia, Yufeng Yuan, Hui‐Chuan Sun, Xuetao Shi, A. Guzmán, Luis Corrales, Zdeněk Král, Peter Priester, Eugen Kubala, Jean Frédéric Blanc, Marc Bourlière, Jean Marie Péron, Christophe Borg, Jean‐Pierre Bronowicki, Nathalie Ganne–Carrié, Thomas Decaens, Thomas Uguen, Alexandra Heurgué (2023). Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. , 402(10415), DOI: https://doi.org/10.1016/s0140-6736(23)01796-8.